Mechanisms and cell lineages in lymphatic vascular development

Daniyal J. Jafree1,2 · David A. Long1 · Peter J. Scambler1 · Christiana Ruhrberg3

Received: 10 January 2021 / Accepted: 10 March 2021 / Published online: 6 April 2021
© The Author(s) 2021

Abstract
Lymphatic vessels have critical roles in both health and disease and their study is a rapidly evolving area of vascular biology. The consensus on how the first lymphatic vessels arise in the developing embryo has recently shifted. Originally, they were thought to solely derive by sprouting from veins. Since then, several studies have uncovered novel cellular mechanisms and a diversity of contributing cell lineages in the formation of organ lymphatic vasculature. Here, we review the key mechanisms and cell lineages contributing to lymphatic development, discuss the advantages and limitations of experimental techniques used for their study and highlight remaining knowledge gaps that require urgent attention. Emerging technologies should accelerate our understanding of how lymphatic vessels develop normally and how they contribute to disease.

Keywords Embryonic development · Endothelial cell · Lymphangiogenesis · Lymphvasculogenesis · Lymphatic vasculature

Introduction
The lymphatic vasculature constitutes a blind-ended vessel network that removes fluid, cells and molecules from the interstitium and returns a proteinaceous fluid termed lymph through lymph nodes into the blood vascular circulation [1, 2]. Lymphatic vessels are comprised of oak leaf-shaped lymphatic endothelial cells (LEC) that are bound by junctions with each other to surround a lumen. The lymphatic vasculature is hierarchical, beginning with blind-ended capillaries adapted for fluid, cell and molecule uptake and transitioning to larger collecting vessels with valves and mural cell coverage for unidirectional lymph transport [3]. An example is the lymphatic vasculature lining the meninges and intervertebral spaces, which clears macromolecules as well as interstitial and cerebrospinal fluid from the central nervous system [4–9]. The importance of lymphatic drainage for central nervous system function is underscored by recent findings that its disruption likely contributes to the sequelae of traumatic brain injury [10], cognitive decline and degenerative neuropathology [11, 12]. Lymphatics are also integral for immunity via immune cell, cytokine and antigen trafficking and by releasing molecules that regulate the inflammatory milieu [13–15]. Accordingly, modulating lymphatic function has therapeutic implications for a broad repertoire of pathologies including autoimmunity [16, 17], cardiovascular disease [18–22] and cancer [23, 24].

In addition to their general role in fluid uptake and immunity, lymphatics fulfill a variety of organ-specific physiological functions. For example, lymphatic vessels in the gastrointestinal system maintain gut immune homeostasis [25] whilst also transporting lipids and fat-soluble vitamins derived from the diet [26], with gut lymphatic function perturbed in obesity [27, 28]. Other examples of organ-specific lymphatic functions include the regulation of hair follicle regeneration by dermal lymphatics [29, 30] and the maintenance of total lung compliance by pulmonary lymphatics, the latter required for lung inflation at birth in preparation for breathing [31]. These key features of lymphatic vasculature highlight the importance of studying lymphatic vessel formation and the emergence of lymphatic heterogeneity during embryonic development.

Here, we review a large body of experimental evidence, which suggests that lymphatics arise by diverse cellular
mechanisms from multiple cell lineages during the extensive period of organ development in the embryo. We emphasise the strengths and limitations of the experimental techniques used to arrive at this knowledge and suggest how future studies might incorporate emerging technologies to further investigate the origin of organ-specific lymphatic functions in health and disease.

**Cellular mechanisms of lymphatic development**

**Techniques and models to visualise lymphatics during embryonic development**

Seminal experiments to understand lymphatic development were conducted at the beginning of the twentieth century. At this time, serial histological sections of ink-injected pig, rabbit or cat embryos were observed with light microscopy to study the origins, distribution and morphology of fluid-filled lymphatic vessels [32–36]. More recently, the mouse has served as the major mammalian model organism, due to its amenability for genetic engineering and the availability of many useful molecular markers for endothelial cells, including LECs. For example, the Prox1^{+lacZ} knock-in mouse expresses β-galactosidase (β-gal) in cells that endogenously express the transcription factor prospero homeobox protein 1 (PROX1), a key marker of LECs [37–39], and has been used to identify lymphatic vessels in tissue sections of developing embryos. Most commonly, lymphatic vessels and individual LECs are identified in tissue sections or embryo and organ wholemounts by immunostaining for antibodies raised against PROX1 as well as other LEC markers, such as vascular endothelial growth factor receptor 3 (VEGFR3; also known as FLT4), the glycoprotein podoplanin (PDPN) [40, 41] or lymphatic vessel endothelial hyaluronidase receptor 1 (LYVE1) [42]. Though none of these molecular markers are exclusive to lymphatic vessels, in combination with one another they can be used to accurately identify LECs. More recently, wholemount immunofluorescence staining with or without tissue clearing has been combined with confocal microscopy, optical projection tomography or light-sheet fluorescence microscopy to produce three-dimensional (3D) images of lymphatic networks in intact mouse organs or entire embryos [43–45]. These modalities allow the detection of all LECs within a tissue and 3D analyses of lymphatic formation at cellular resolution, thus providing experimental advantages to ink injection, which allows the visualisation of fluid-filled vessel lymphatic networks but cannot identify single-cell precursors or newly formed lymphatic vessel segments that are not yet fluid-filled.

Many insights into the mechanisms of lymphatic development have also arisen from live imaging of developing zebrafish larvae, which are transparent and thus exquisitely suited for live imaging of dynamic cellular behaviours, including the processes that occur during lymphatic development. More specifically, using zebrafish with transgenes that express fluorescent proteins from lymphatic promoters, such as lyve1:EGFP or lyve1:DsRed2 [46], allows LECs to be directly visualised at high resolution in vivo with time-lapse confocal microscopy. Such studies have shown that zebrafish possess a lymphatic system that shares key structural and functional features with its mammalian counterpart [47, 48]. Examples of functional similarities include the ability of zebrafish lymphatic vessels to clear injected dyes from extracellular spaces [9, 47–50] and the presence of collecting vessels with valves for unidirectional lymph flow [51].

By utilising the above visualisation techniques to study genetically modified mice and zebrafish, many insights into evolutionary conserved molecular and cellular mechanisms of lymphatic development have been gathered, which we discuss in this review.

**Mechanistic hallmarks of lymphatic vessel assembly in mammals**

Based on work using the experimental approaches described above, it is now widely accepted that lymphatic vessels in mammals arise through several distinct but complementary cellular mechanisms (Fig. 1). These events are instructed by several key molecules, whose specific roles are described below (see also Table 1).

**Venous specification**

Early experiments in pig and rabbit embryos led to the ‘venous’ model of lymphatic development, based on the observation that ink injection of superficial lymphatic vessels traced connections to blind ducts budding from venous endothelium [32–35]. Subsequently, multiple studies have used histological techniques in mice to confirm that lymphatic development begins by venous specification and pinpointed this to occur between embryonic day (E)9.5 and 10.0, shortly after the specification of the major arteries and veins [52] and around the timing of cardiac septation [53] (Fig. 1a). These studies employed immunostaining of tissue sections or wholemount preparations from Prox1^{+fluGZ} or wildtype embryonic mice to demonstrate that a subpopulation of cells in the anterior wall of the cardinal vein and the adjacent intersomitic veins begin to express PROX1 [37, 38, 44, 54]. In this subpopulation of venous cells, PROX1 is co-expressed with two other transcription factors, sex determining region Y box (SOX)18 and chicken ovalbumin upstream promoter transcription factor II (Coup-TfII, also known as Nr2f2). These transcription factors interact with one another to
drive venous endothelial cells to differentiate into lymphatic progenitors [55–58]. The commitment of venous cells to a LEC fate is negatively regulated by folliculin (FLCN), which prevents the accumulation and nuclear translocation of the transcription factor E3 (TFE3) that promotes Prox1 expression [59]. Accordingly, loss of FLCN causes excessive commitment of venous endothelial cells to LECs and also promotes LEC proliferation [59]. Whilst within the wall of the cardinal vein, lymphatic progenitors also begin to express LYVE1, which serves as a useful molecular marker for lymphatic vessels, but is not known to be required for the venous specification of endothelium [60] (Table 1).

Lymphangiogenesis

At the next stage of lymphatic development, lymphatic progenitors exit from the cardinal vein and coalesce to form the first lymphatic vessels (Fig. 1b). This process was first observed in immunolabelled tissue sections of E10.5 ProxI+Cre and wildtype mouse embryos [37, 38]. By E11.5, these progenitors have migrated dorsally and anteriorly as interconnected cells and condense into structures adjacent to the cardinal vein that appear as sacs when viewed in tissue sections [45, 54]. This process was subsequently re-evaluated by high-resolution 3D imaging of immunolabelled and optically cleared mouse embryos with light-sheet fluorescence microscopy [44]. These experiments showed that lymphatic progenitors sprout from along the length of
| Molecule      | Venous specification | Lymphangiogenesis                                                                 | Lymphvasculogenesis |
|--------------|----------------------|-----------------------------------------------------------------------------------|---------------------|
| ADAMTS3      | No role established  | Required for lymphangiogenesis by facilitating proteolytic cleavage of VEGF via CCBE1 [74–76] | No role established |
| CCBE1        | No role established  | Required for budding and sprouting of LECs from veins [44] by facilitating proteolytic cleavage of VEGF [74, 75, 77] | Required for the exit of lymphatic cluster-forming LECs from the cervicothoracic dermal capillary plexus [78] |
| COUP-TFII    | Directly binds Prox1 and promotes its activation for LEC differentiation [55, 58] | Regulates Nrp2 transcription, required for LECs sprouting and proliferation, and required to maintain LEC fate [73] | No role established |
| FLCN         | Supresses nuclear translocation of TFE3, which binds to Prox1 and stimulates LEC differentiation [59] | No role established | No role established |
| GATA2        | No role established  | Regulates migratory responses in LECs and directly regulates VEGFR3 expression [70] | No role established |
| LYVE1        | No role established  | Not absolutely required for lymphangiogenesis [60] | No role established |
| NRP2         | No role established  | Facilitates lymphatic sprouting as a co-receptor for VEGFR3 in VEGF signalling [71, 72] | No role established |
| PDPN         | No role established  | Involved in the platelet-mediated separation of lymphatics from the blood vasculature during lymphatic sprouting [160] | No role established |
| PROX1        | Represses blood endothelial identity and induces LEC fate [37, 38] | Acts in a feedback loop with VEGFR3 and required to maintain LEC specification [39, 69] | Expressed in cluster cells [8, 43, 79, 81, 82] and deletion in the second heart field lineage causes ventral cardiac lymphatic agenesis [99], therefore is likely required for lymphatic cluster formation |
| SOX18        | Promotes Prox1 expression in venous ECs and induces LEC fate specification [57] | No role established | No role established |
| VEGFC        | No clear role as VEGF mutations have lymphatic progenitors in the wall of the cardinal vein [44, 66] | Essential for the sprouting of LEC progenitors from venous endothelium LECs [44, 66] | Promotes lymphatic cluster expansion and number [43, 78] |
| VEGFR3       | Acts in a feedback loop with PROX1 to maintain LEC identity whilst in the wall of the vein [69] | Acts cell-autonomously and non-cell-autonomously for LEC proliferation, migration and survival [67–69] | No role established |

ADAMTS3 A disintegrin and metalloprotease with thrombospondin motifs-3, CCBE1 collagen and calcium-binding EGF domain-containing protein 1, COUP-TFII COUP transcription factor 2, LYVE1 lymphatic vessel endothelial hyaluronan receptor 1, EC endothelial cell, FLCN folliculin, GATA2 GATA-binding factor 2, LEC lymphatic endothelial cell, NRP2 neuropilin 2, PDPN podoplanin, PROX1 prospero homeobox protein 1, SOX18 sex determining region Y box 18, TFE3 transcription factor E3, VEGFC vascular endothelial growth factor C, VEGFR3 vascular endothelial growth factor receptor
the cardinal vein as groups of spindle-shaped cells, and that they condense into the continuous primordial thoracic duct, the main axillary lymphatic vessel, and the paired peripheral longitudinal lymphatic vessels, rather than discrete lymph sacs [44]. Sprouting of LECs dorsally from the peripheral longitudinal lymphatic vessels was further shown to give rise to a superficial lymphatic plexus [44]. The process of lymphatic sprouting from pre-existing lymphatic vessels has been termed lymphangiogenesis [61], in analogy to the angiogenic process by which blood vessels sprout [62]. In both angiogenesis and lymphangiogenesis, filopodia-studded endothelial cells lead new vessel sprouts that emerge from a pre-existing vascular network in which endothelial cells proliferate.

As lymphangiogenesis was initially thought to be the predominant mechanism by which lymphatic vessels arise [63], the molecules driving this process have been extensively studied using genetic knockout experiments (Table 1). Whilst blood vessel angiogenesis is a VEGFR2-driven response of endothelial tip cells [64] to VEGFA gradients [65], lymphangiogenesis involves a VEGFR3 response to VEGFC signals [66–68]. Mesenchyme adjacent to the cardinal vein secretes VEGFC [66], which binds to VEGFR3 on the cardinal vein to promote the sprouting, proliferation, migration and survival of LECs [68, 69]. Several molecules promote VEGFC signalling in LECs. To increase VEGFC responsiveness, the transcription factor GATA-binding factor 2 (GATA2) promotes VEGFR3 expression in LECs as they exit the cardinal vein [70]. Further, neuropilin (NRP)2 acts as a co-receptor for VEGFR3 to promote VEGFC-dependent lymphatic sprouting [71, 72], whereby NRP2 expression is up-regulated by COUP-TFII [73]. The secreted protein collagen and calcium binding EGF domains 1 (CCBE1) activates the A disintegrin and metalloproteinase with thrombospondin motifs 3 (ADAMTS3), which in turn promotes the proteolytic cleavage of the otherwise poorly active 29/31 kDa form of VEGFC to its active 21/23 kDa form [74–77].

Lymphvasculogenesis

Combining wholemount immunostaining with confocal imaging of developing mammalian organs brought to light a complementary cellular mechanism of lymphatic development. In particular, imaging of developing mouse skin [78–80], mesentery [81] heart [82], lung [83], intestine [84] meninges [8, 85] and kidney [43] revealed islands of individual LECs that appeared to coalesce into lymphatic vessels (Fig. 2). Lymphatic clusters in the mesentery, meninges and dermis contain proliferating cells [8, 78, 81] and cluster cells extend protrusions towards other clusters or nearby lymphatic vessels [8, 43, 78, 79, 81] (Fig. 2). These protrusions might function similarly to filopodia on blood vessel tip cells to initiate fusion [62]. Quantitative analysis of kidney, mesentery and dermis showed that the abundance of clusters declines as the lymphatic plexus expands through gestation [8, 43, 78]. Altogether, these findings suggest that cluster LECs proliferate and fuse, both with each other and to pre-existing lymphatic vessels, to expand organ lymphatic networks. This process has been termed lymphvasculogenesis [3] due to its similarity to vasculogenesis, a process by which blood vascular endothelial cells differentiate from single cell precursors and then coalesce. Notably, lymphatic clusters without discernible physical connections to sprouting lymphatic vessels were also observed in the human embryonic kidney [43], suggesting that lymphvasculogenesis is also an important mechanism for human lymphatic development, albeit other human organs have not yet been examined for such structures. Given its recent discovery, the molecular mechanisms underpinning lymphvasculogenesis remain poorly understood, but recent studies have begun to identify molecules that affect lymphatic cluster formation (Table 1). For example, it was shown that CCBE1 loss abrogates dermal lymphatic cluster formation in mice, whereas this process was increased by endothelial VEGFC
overexpression [78]. VEGFC is therefore likely a universal regulator of LEC proliferation. An area that warrants further study pertains to evidence suggesting that sex [19] and genetic background [43, 57, 86] could affect lymphangiogenesis and lymphvasculogenesis in mice.

**Mechanistic hallmarks of lymphatic vessel assembly in zebrafish**

Live imaging during early lymphatic development in zebrafish has provided novel insights into the cellular dynamics of venous specification and lymphangiogenesis (Fig. 3a). For example, time-lapse imaging of transgenic zebrafish expressing fluorescent proteins controlled by the promoter of *prox1a*, an orthologue of mammalian *Prox1*, localised the first lymphatic progenitors to the ventral wall of the posterior cardinal vein at 22–24 h post-fertilisation (hpf) [87, 88]. These progenitors undergo asymmetric division and translocate to the dorsal wall of the vein [87, 88]. Live imaging of a *fucci* reporter, which identifies cells in specific stages of the cell cycle, showed that lymphatic progenitors undergo cell cycle arrest prior to emigrating from the posterior cardinal vein [89]. Upon their exit from the vein, LECs migrate along intersomitic arterial vessels, in a manner dependent on Vegfc [47, 48, 87, 90] and Cxcl12a and Cxcl12b gradients [91], and form the lymphatics of the zebrafish trunk via lymphangiogenesis [47, 48, 50]. These cellular dynamics largely agree with the mechanisms inferred from fixed mouse tissues.

At later stages, time-lapse imaging of the developing facial lymphatic network has demonstrated that lymphvasculogenesis also occurs in fish to complement lymphangiogenesis (Fig. 3b). Live imaging of lyve1:EGFP transgenic zebrafish embryos showed that facial lymphatic vessels sprout from the cardinal vein from 36 hpf and fuse with lymphatic clusters that arise from the primary head sinus at 48 hpf. Additionally, a different population of lymphatic clusters arises at 72 hpf adjacent to the ventral aorta, and these clusters migrate towards and coalesce with venous-derived lymphatic vessels [46, 92].

Despite overall conservation of key mechanisms in lymphatic development between mouse and zebrafish, the genetic knockdown of some genes implicated in lymphatic development in mouse cause only mild lymphatic phenotypes in zebrafish [87, 93, 94]. Such differences might be explained by the persistence of maternal transcripts that

---

**Fig. 3** Insights from zebrafish into the cellular dynamics of lymphatic development. **a** Formation of trunk lymphatic vessels: (i) A subset of angioblasts seeds the floor of the cardinal vein to give rise to endothelial cells, which begin to adopt a LEC identity from 22 hpf onwards; (ii) these progenitors undergo asymmetric division and give rise to lymphatic progenitors that migrate to the dorsal wall of the vein (the dotted line indicates cell division); (iii) these lymphatic progenitors give rise to parachordal lymphangioblasts (PAC); (iv) the PACs sprout along adjacent arterial endothelial cells (EC). The inset shows that lymphatic progenitors in the cardinal vein undergo cell cycle arrest and give rise to PACs that sprout, driven by gradients of Vegfc and the chemokines Cxcl12a and Cxcl12b. **b** Formation of facial lymphatic vessels: (i) Facial lymphatic sprouts emerge from the cardinal vein by 36 hpf; (ii) lymphatic clusters emerge from the primary head sinus by 48 hpf and fuse with the cardinal vein-derived lymphatic sprout; (iii) lymphatic clusters arise adjacent to the ventral aorta by 72 hpf and (iv) migrate towards and (v) fuse with the growing venous-derived lymphatic sprout to form the facial lymphatic network.

---
reduce the penetrance of genetic mutations in the zebrafish [87] or the presence of duplicated genes in the zebrafish genome which compensate for one another [95, 96]. Alternatively, different phenotypes may be due to evolutionary divergence in the requirement of certain molecules for lymphatic development [97].

**Cell lineages contributing to lymphatic endothelium**

Whereas lymphangiogenesis of venous-derived LECs was initially considered the predominant mode of lymphatic development [63], the discovery of lymphvasculogenesis has prompted re-examination of the cellular origins of LECs in recent years. Experiments facilitated by genetic lineage tracing suggest that paraxial mesoderm is the precursor of venous-derived LECs in the mouse [80] and that non-venous progenitors provide additional cellular LEC sources for organ lymphatic formation (Fig. 4). Before we discuss these findings in more detail, we provide an overview of the main experimental strategy for genetic lineage tracing of mammalian lymphatics, which utilises the Cre-loxP recombination system in mouse.

**Lineage tracing lymphatic origins via Cre-loxP recombination in mouse**

The Cre enzyme from the P1 bacteriophage is a site-specific recombinase that excises DNA segments flanked by loxP sites [98]. For genetic lineage tracing, Cre is expressed under the control of a promoter that drives cell-type specific gene expression, either from a transgene or when knocked directly into the endogenous locus. This strategy is used to recombine reporter genes, in which a loxP-flanked stop codon precedes the coding sequence of a non-mammalian protein, such as β-galactosidase, or the fluorescent proteins GFP and tdTomato. Accordingly, the reporter protein is only present in Cre-expressing cells and their descendants to facilitate lineage tracing.

The *Tie2-Cre* transgenic mouse has been used for genetic lineage tracing to demonstrate the venous origin of LECs during early lymphangiogenesis [63] as well as during cardiac [22, 99] and dermal [78, 79] lymphatic development. This strategy was based on the observation that transcripts for tyrosine-protein kinase receptor (TIE)2 are enriched in venous relative to arterial endothelium [100]. Moreover, in situ hybridisation for *Tie2* and immunostaining of *Tie2-GFP* mice have not detected *Tie2* expression in LECs budding from the cardinal vein or lymphatic vessels of E11.5 to E15.5 embryos [63, 78]. When *Tie2-Cre* mice are bred with a *R26R* reporter line, the encoded β-galactosidase is active in the anterior cardiac vein, in LECs budding from the cardinal vein at E11.5 and in PROX1+ cells of adjacent lymph sacs at E13.5 and E14.5 [63]. These studies therefore corroborate that LECs can be derived from a *Tie2* lineage of venous progenitors. In the future, recently identified venous-specific promoter or enhancer sequences [101] may provide alternative, more specific lineage tracing tools for venous endothelial derivatives. Notably, TIE2 has been detected by immunostaining in adult mouse ear LECs [102]. Therefore, it will be important to determine whether LEC labelling with *Tie2-Cre* can be caused by TIE2 expression in LECs in some organs.

Temporal control was subsequently introduced into the Cre-loxP system by fusing a modified estrogen receptor ligand binding domain to Cre (CreER), so that Cre is retained in the cytoplasm until bound by an ER agonist, typically hydroxytamoxifen (4-OHT); in its agonist-bound form, Cre is then translocated to the nucleus as a prerequisite for Cre-induced genomic DNA recombination [98]. The most popular version of CreER, CreERT2, carries point mutations that reduce binding of endogenous estrogen. The promoters of the endothelial genes encoding platelet-derived growth factor (PDGF)B [22, 81], apelin receptor (APJ) [82], cadherin 5 (CDH5) or SOX18 [78] have all been used for lineage tracing of LECs, whereby 4-OHT or its precursor, tamoxifen, are administered to mice pregnant with embryos carrying both CreERT2 and a Cre-dependent reporter.

CreERT2-based genetic lineage tracing can be performed in specific gestational windows to discriminate between different cellular origins of lymphatics based on their temporal emergence. For example, a tamoxifen pulse administered to activate *Vegfr3-CreERT2* in E14.5 mouse embryos labelled LECs in both the dorsal and ventral heart at E17.5 [103]. By contrast, an earlier tamoxifen pulse at E11.5 or E12.5 predominantly labelled dorsal, but not ventral LECs, suggesting that ventral LECs arise at a later timepoint [103]. Further, administration of 4-OHT to E15.5 embryos carrying *Prox1-CreERT2* labelled established dermal lymphatic vessels at E17.5, but lymphatic clusters in the midline were not labelled; these findings suggest that lymphangiogenesis and lymphvasculogenesis in the dermis occur from mutually exclusive cell lineages [79]. The duration of Cre recombination in these experiments, however, must be considered when interpreting the findings, because the estimated half-life of tamoxifen in mice ranges from 6 to 16 h, depending on the route of administration and dose, whilst 4-OHT clearance occurs in a shorter timeframe [79, 104–106]. Thus 4-OHT administration may be desirable to capture a lineage within a short developmental window, whereas tamoxifen might be appropriate for maximal recombination over a longer timeframe.

Despite the advantages of the Cre-loxP system to identify cell lineages, the complexity of gene expression patterns during embryonic development makes it unlikely that the
**Fig. 4** Cellular lineages contributing to lymphatic endothelium in mouse.  

**a Paraxial mesoderm:** (i) The paraxial mesoderm (PXM) is a transient cell population located between the intermediate mesoderm (IM) and the neural tube (NT) and gives rise to muscle lineages and limb endothelium; (ii) based on lineage tracing from the *Pax3* promoter, the PXM is proposed to contribute venous endothelial cells (ECs) to the dorsolateral wall of the cardinal vein, whereas the rest of the vein is derived from lateral plate mesoderm (LPM). Thereby, the *Pax3* lineage gives rise to most LECs in the heart, liver and lung as well as thoracic, lumbar and sacral skin.  

**b Second heart field:** The cells of the second heart field (SHF), located adjacent to the first heart field (FHF), contribute to the poles of the developing heart. Based on lineage tracing with the *Isl1* and *Mef2c* promoters, LECs from the SHF are proposed to contribute LECs to the ventral surface of the heart and the cervicothoracic region of the dermis. It is not yet known whether the SHF lineage contributes cells to lymphovasculogenesis in the heart.  

**c Hemogenic endothelium:** Hemogenic endothelia in the yolk sac and several intraembryonic sites give rise to circulating KIT+ progenitors with the potential to differentiate into erythrocytes and myeloid cells. Based on lineage tracing from the KIT promoter using an inducible *Kit-CreER<sup>T2</sup>* allele, hemogenic EC-derived progenitors are proposed to give rise LECs in lymphatic vessels and clusters of the mesentery. Based on lineage tracing from the haematopoietic *Csf1r* and *Vav1* promoters, hemogenic EC-derived progenitors are proposed to give rise to LECs within cardiac lymphatic vessels, but the contribution of these lineages to lymphatic clusters in the heart has not yet been examined.  

**d Dermal capillary plexus:** Based on lineage tracing from the *Pax3* promoter, the PXM is proposed to contribute to dermal blood vascular capillaries which then give rise to dermal LECs via a VEGFC/CCBE1-dependent budding mechanism.
expression of a single gene accurately demarcates any cell lineage with high specificity; this caveat, in turn, will generate some ambiguity when interpreting reporter labelling to deduce lymphatic origins. For example, TIE2, PDGFB and CDH5 are not specific to veins, but are also expressed in capillaries and hemogenic endothelium [107–109]. This knowledge is pertinent, given the deduction that non-venous endothelium is a putative source of lymphatics in multiple mouse organs [22, 78, 79, 81]. Moreover, LECs themselves express CDH5, and some LECs also express PDGFB [54, 110–113], raising the possibility that some lymphatic recombination after Cdh5-CreERT2 and Pdgfb-CreERT2 activation can be attributed to Cre expression in LEC themselves.

Other limitations of the Cre-loxP system include potential ectopic Cre activity when transgenes containing Cre insert into genetic loci that inadvertently modify transgene promoter activity, or when recombination unexpectedly occurs in the germline [114, 115]. Spontaneous CreER[T2] translocation to the nucleus, in the absence of tamoxifen, may also confound the interpretation of lineage tracing studies [116]. Incomplete recombination due to suboptimal 4-OHT administration or different bioavailability in different organs [117, 118] may also affect the efficiency of genetic lineage tracing. Conversely, deleterious effects to the embryo occur from the toxicity of high levels of tamoxifen, 4-OHT or their delivery vehicles [119–121]. Toxicity can also arise when Cre recognises genomic sequences resembling loxP sites to cause DNA breaks [122], especially when Cre is expressed highly, or when random genomic insertion of transgenes disrupts essential endogenous genetic loci [123]. Unexpected phenotypes arising from these deleterious effects, which may vary according to the genetic background of the mice, may further affect the interpretation of lineage tracing studies. Although specific examples of these scenarios have not yet been reported for lymphatic development, tamoxifen-induced CreER activation impairs postnatal blood vascular growth [124]. The limitations of Cre-mediated genetic lineage tracing and potential solutions to improve studies involving this technique are listed in Table 2.

**Defining how venous-derived lymphatics are first specified**

The first intra-embryonic endothelial progenitors are thought to arise from hemangioblasts in lateral plate mesoderm [125], which then condense as blood vascular endothelial cells into the paired dorsal aortae and cardinal veins from approximately E7.5 onwards [126]. Therefore, it has been hypothesised that lateral plate mesoderm might be the source of the first LECs that emerge from the cardinal vein. Zebrafish experiments supporting this hypothesis have taken advantage of a photoconvertible Kaede protein expressed under the control of the promoter for kinase insert domain receptor like (kdrl), which encodes an endothelial VEGF receptor that is not orthologous to mammalian KDR [88]. A pulse of ultraviolet light photoconverts Kaede from green to red, and the immediate progeny of photoconverted cells, which inherit the protein, also remain red, thus providing a means of evaluating cell lineage. Photoconversion of kdrl-expressing cells located lateral to the dorsal aorta, a region containing presumed lateral plate mesoderm-derived angioblasts [95], also labelled lymphatic progenitors in the zebrafish trunk [88]. This finding was interpreted to suggest that lymphatics are derived from lateral plate mesoderm. However, is not clear whether this approach can distinguish cells arising from lateral plate mesoderm or from other mesodermal sources nearby. Experiments involving homotypic transplantation from quail into chick embryos refute that lateral plate mesoderm is the origin of lymphatics in avian species. Specifically, LECs within the jugular region of the developing chick wing were not found to express quail antigens after transplantation of lateral plate mesoderm from quail [127], but did so after transplantation of somites [128].

The concept that somitic precursor cells give rise to LECs has gained support from a recent mouse study, in which Cre was constitutively expressed from the promoter of paired box protein (Pax)3 [80]. This study reported that endothelial cells in the dorsolateral wall of the cardinal vein at E9.5 were derived from a Pax3 lineage, as were LECs emigrating from the cardinal vein at E10.5 [80]. As PAX3 protein is expressed in the paraxial mesoderm that gives rise to somitic cells, but is not present in the endothelial cells themselves [80], it was concluded that venous LEC progenitors arise from the paraxial mesoderm (Fig. 4a). Pax3 lineage tracing further suggested that the vast majority of dermal and cardiac LECs derive from paraxial rather than lateral plate mesoderm [80], albeit the proportion of Pax3 lineage-derived LECs was not quantified for these organs. The Pax3 lineage also included LECs in lumbar clusters [80], raising the possibility that the paraxial mesoderm also gives rise to LECs via lymphvasculogenesis.

Several challenges still remain. Firstly, additional work is required to demonstrate that lack of PAX3 protein in endothelial cells extends to transcript levels, as a prerequisite to exclude Pax3 promoter activity in endothelial cells themselves. Secondly, it should be considered that Pax3-mediated constitutive Cre expression is not exclusive for detecting paraxial mesoderm derivatives. Thus, it is important to identify all embryonic progenitor populations captured by the Pax3 lineage and perform complementary lineage tracing approaches. Such lineage tracing studies should include inducible CreER approaches to narrow down the developmental window during which LEC precursors express Pax3. Additionally, it would be desirable to corroborate that paraxial mesoderm is the only Pax3-expressing population that gives...
rise to LECs to determine if paraxial mesoderm is the only source of Pax3-expressing LEC progenitors. For example, neural crest cells also express PAX3, but these cells do not give rise to lymphatics, because the pan-neural crest promoter Wnt family member (Wnt) 1 did not capture LECs, at least in the heart [22]. Similar experiments might be performed for other candidate Pax3 expressing cell lineages, should they exist. Another challenge is to identify the origin of LECs that are not captured by the Pax3 lineage, including the lymphatics of the meninges, ear skin, mesentery and intestines [80].

**Non-venous origins of lymphatic endothelial cells**

Although Pax3 lineage tracing suggested that the vast majority of LECs are derived from paraxial mesoderm, the second heart field [80, 99, 103], hemogenic endothelium [22, 81] and blood capillaries within the dermis [78] have also been proposed to contribute to the lymphatic vasculature.

**Second heart field**

During cardiac development, the elongation of the primitive heart tube and eventual septation of the heart requires a contribution from extracardiac progenitor cells in the lateral plate mesoderm. This population is termed the second heart field and is a source of smooth muscle, endothelial and myocardial cells for the arterial and venous poles of the developing heart [129]. Recently, several genetic lineage tracing studies suggested that a second heart field progenitor contributes to cardiac lymphatics (Fig. 4b).

Two lymphatic lineage tracing studies used a constitutively active insulin gene enhancer protein (Isl1)-Cre, which is expressed in the second heart field [130]. These studies suggested that half of all LECs on the ventral cardiac surface

---

**Table 2** Limitations of Cre-loxP lineage tracing in mouse and potential solutions

| Problem                        | Possible reasons                                                                 | Solution                                                                                     |
|-------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Unexpected cell types captured by lineage trace | Expression of gene promoter driving Cre occurs in other, off-target cell types | Thorough characterisation of expression of gene driving Cre expression or its product       |
|                               | Ectopic activity of Cre transgene due to modification of promoter activity in genetic locus | Use of other complementary Cre drivers to validate results; use of alternative transgenes or knock-in alleles |
|                               | Spontaneous translocation of CreER to nucleus in the absence of tamoxifen | Comparison with vehicle-only controls                                                        |
|                               | Spontaneous recombination of reporter alleles in the absence of Cre | Quantification of recombination in the absence of Cre; use of alternative and complementary reporter alleles |
|                               | Unexpected recombination of Cre in the germline | Inheritance of Cre from alternative sex or use of inducible CreER                              |
| Target cell population not captured by lineage trace | Inefficient recombination of CreER alleles | Increase tamoxifen or 4-OHT dose, selection of alternative CreER line or use of constitutively active Cre |
|                               | Time-window of tamoxifen or 4-OHT and CreER activity not coincident with target cell population | Optimising of timing and dosage of tamoxifen or 4-OHT                                        |
|                               | Poor bioavailability of 4-OHT or CreER in target tissue | Using alternative method of tamoxifen or 4-OHT delivery; increase tamoxifen or 4-OHT dose  |
| Phenotype or abortion of lineage traced embryos | Random insertion of transgene into critical genetic locus | Comparison with appropriate controls lacking Cre expression; selection of alternative Cre line |
|                               | High levels of Cre or CreER induction causing DNA damage | Ensure Cre-expressing embryos are heterozygous or hemizygous and titrate tamoxifen or 4-OHT levels to limit CreER activation |
|                               | Haploinsufficiency due to heterozygous loss of function in knock-in allele | Comparison with appropriate controls lacking Cre expression; selection of alternative Cre line |
|                               | Teratogenicity of tamoxifen or 4-OHT; detrimental effect of vehicles on pregnancy (e.g., peritoneal inflammation) | Titration of tamoxifen or 4-OHT dosage by weight or age of reporter mouse; co-administration of progesterone for early pregnancy; reduce volume of vehicle used for delivery |
have a different origin [99, 103]. These conclusions were strengthened when inducible Isl1-CreER was tamoxifen-activated at E8.5, when the second heart field has formed but before the onset of LEC differentiation, because ventral cardiac LECs were also lineage-traced [103]. However, ISL1 is also expressed in pharyngeal and foregut endoderm at E8.5 [130], and it was therefore important that the second heart field origin of cardiac LECs was corroborated with a constitutively active Cre expressed under the control of a myocyte enhancer factor 2c (Mef2c) regulatory region that confers specific expression to the anterior region of the second heart field (Mef2c-AHF-Cre) [131]. These experiments showed that the Mef2c lineage includes a small proportion of LECs on the ventral, but not the dorsal surface of the mouse embryo heart [80, 103]. However, further investigation is required to determine why a smaller proportion of LECs is detected with Mef2c-AHF-Cre compared to Isl1-Cre.

It further remains to be established whether second heart field-derived progenitors undergo lymphvasculogenesis to form the lymphatic clusters recently described in the mouse embryonic heart [82], or whether there is an intermediate cell population, such as second heart field-derived blood endothelial cells [132], which secondarily gives rise to cardiac LECs, akin to the venous [63] or capillary [78] origin of lymphatics in other parts of the embryo. Further, it has to be considered that lymphatic vessels in the cervical skin, jugular and facial regions also contain LECs that are lineage-traced by Mef2c-AHF-Cre and Isl1-Cre [80, 99]. Therefore, it would be important to ascertain that these transgenes are not active in venous endothelium, paraxial mesoderm or other cell types with the potential to form lymphatics.

Hemogenic endothelium

During mammalian development, blood vessels in the yolk sac, umbilical vessels and aorta-gonad-mesonephros region give rise to so-called hemogenic endothelial cells, which generate circulating hematopoietic progenitors with the potential for myeloid, lymphoid, erythroid and blood endothelial differentiation [133]. Although lineage tracing of hemogenic endothelium is challenging due to shortcomings of individual tools used to trace its derivatives, the collective results obtained by lineage tracing with multiple different inducible and constitutively active Cre lines implicates circulating progenitors from hemogenic endothelium as a source of LECs in the heart [22] and mesentery [81] (Fig. 4c).

An inducible Cre knock-in allele utilising the promoter of the hemogenic endothelial cell surface protein KIT (Kit-CreERT2), when induced with tamoxifen at E10.5, labelled lymphatic clusters in the E13.5 mesentery, but only in 29% of embryos [81]. Low labelling efficiency might be explained by inefficient recombination. In agreement, we found that the Kit-CreERT2 allele requires high doses of tamoxifen or 4-OHT for efficient activity [133]. Notably, it has recently been reported that Kit is also expressed in some non-hemogenic blood vascular endothelial cells at E12.5 [134], which may have been captured when a high dose of tamoxifen is given at E10.5. Moreover, it is not clear when during development Kit is first expressed in a subset of non-hemogenic blood vascular endothelial cells. Further knowledge of the precise spatiotemporal Kit expression pattern in blood and lymphatic endothelia and a refined time window of Kit-CreERT2 induction might therefore help to demonstrate specificity of individual Kit-based lineage tracing for hemogenic endothelia and therefore to corroborate the origin of LEC subsets from this source.

In another study, a constitutively active Cre under the control of the promoter for the gene encoding the hematopoietic progenitor marker Vav guanine nucleotide exchange factor 1 (VAV1) was found to capture 15% of cardiac LECs [22], therefore supporting the hemogenic origin of a subset of LECs. As VAV1 is expressed in hematopoietic progenitors after budding from hemogenic endothelium [135], this approach may not have captured all hemogenic endothelium-derived LECs. In support of this idea, Vav1-Cre did not label mesenteric LECs [81]. Similarly, lineage tracing studies utilising tamoxifen-inducible lineage tracing from the promoter of the gene encoding the colony stimulating factor 1 receptor (CSF1R), active in hemogenic endothelium-derived progenitors, labelled only 5% of cardiac LECs [22]. Such limitations, in addition to the temporally overlapping hemogenic endothelial activity of the yolk sac, umbilical vessels and aorta-gonad-mesonephros [136], have obscured the precise identity and prevalence of hemogenic endothelial progenitors for LECs.

Blood capillaries

Blood capillaries have recently been proposed to give rise to dermal LECs in the cervical and thoracic regions (Fig. 4d). Inducing Prox1-CreERT2 with 4-OHT at E12.5 identified a rare population of PROX1-expressing LEC progenitors within the walls of dermal capillaries [78]. Further lineage tracing with Cdh5-CreERT2 identified a population of Cdh5 lineage blood capillary endothelial cells expressing PROX1 [78]. The authors further found that VEGFC promoted LEC exit from dermal capillaries, and that CCBE was required for this process [78]. By inducing the pan-endothelial Sox18-CreERT2 transgene at E9.5, when the first lymphatic progenitors are specified in the cardinal vein, the authors lineage-labelled dermal LECs both in lymphatic clusters as well as lymphatic vessels of the cervical and thoracic regions [78]. A similar result was obtained with Tie2-Cre, despite the absence of detectable TIE2 expression in dermal LECs [78]. These findings led the authors to conclude that dermal
blood capillaries contain LEC progenitors, and that these are capable of giving rise to lymphatic clusters, akin to the LECs that arise in the cardinal vein during lymphangiogenesis [44]. However, the poor suitability of mouse embryos for live imaging at the stages examined precludes unequivocal proof that LECs exit from the dermal capillary wall to form clusters via lymphvasculogenesis in addition to undergoing lymphangiogenesis. As intersomitic veins also exist at the timepoints examined in the study, LECs in the cervical and thoracic dermis could also, at least in part, arise by sprouting from venous endothelium to complement the dermal capillary-derived LEC pool. Notably, another study showed that only 70% of LECs in the lumbar dermis were labelled by Tie2-Cre [79]. It is not known whether the discrepancy between both studies is explained by variable activity of the Tie2-Cre transgene or the reporter alleles [137]. Alternatively, there may be rostrocaudal heterogeneity, whereby some LECs in the lumbar dermis region selectively derive from a lineage that does not express Tie2. Accordingly, further work is required to reconcile these differences.

**Future directions**

Lymphvasculogenesis was recently identified as an alternative and complementary cellular mechanism to lymphangiogenesis during the formation of the lymphatic vascular system. Moreover, a wide range of diverse cell lineages have been suggested to contribute LECs to the lymphatic vasculature in different organs. Accordingly, it is now pertinent to investigate the relative importance and interplay between lymphvasculogenesis and lymphangiogenesis, both for lymphatic development, and also to define how diverse lymphatic origins may impact on morphological and functional lymphatic heterogeneity in different organs for health and disease. For some cell types, lineage origins have been shown to impact on cellular function. For example, macrophages emerge in sequential waves from multiple distinct lineages, whereby lineage origin dictates whether macrophages become tissue-resident or differentiate from circulating monocytes [138]. However, it is not yet known whether differences in the cellular origin of LECs contribute to lymphatic vessel heterogeneity. Alternatively, a wide variety of lineages may be employed to generate LECs, simply to increase their overall number or to improve organ colonization. Another key question is to what extent findings from model organisms can be extrapolated to humans, given that only a few studies have investigated human lymphatic development to date [43, 139–141], likely owing to the limited availability of human fetal tissues. Below, we propose how several emerging technologies might provide a means to help close current gaps in our knowledge of lymphatic development.

**Ex vivo approaches**

To date, our understanding of the cellular dynamics in mammalian lymphatic development is largely based on interpretation of static images from immunolabeled mouse or human tissues combined with extrapolation from zebrafish. Explant culture of developing organs may provide a novel approach to directly investigate such dynamics in mammals. For example, it has been demonstrated that isolated clusters of LECs are present in explanted E14.5 mouse kidney [43] and heart [103] and survive in tissue culture for several days. Accordingly, their coalescence into lymphatic vessels might be observed by live imaging ex vivo, especially when combined with advances in live imaging for deeper laser light penetration into tissues, such as multiphoton microscopy and light-sheet microscopy [142]. As precedence for the utility of this approach, it was shown that transplanting embryonic mouse cardiac mesothelium, but not epicardium, onto the ventral surface of explanted mouse embryo hearts gave rise to LEC clusters; a finding suggesting that some, but not all, cardiac tissues contain progenitors for lymphvasculogenesis [103]. The development of bioreactors or microfluidic systems [143] to better mimic blood flow and interstitial fluid accumulation [144] may further enhance lymphatic morphogenesis in such experiments. Ex vivo organ culture may also help to identify molecules required for lymphvasculogenesis, because the molecular regulation of this process remains poorly understood relative to lymphangiogenesis. For example, recombinant VEGFC increases the number of lymphatic clusters in explanted E14.5 mouse kidneys [43]. A tissue culture setting also provides relatively simple means for targeted genetic manipulation, for example, by photoactivation [145, 146] of explanted mammalian organs, analogous to the Kaede system used to study lymphatic development in zebrafish.

**Single cell technologies**

Despite tremendous progress in defining the cellular lineages that give rise to lymphatics, identifying candidate progenitors and suitable promoters to drive Cre expression has traditionally relied on deduction or serendipity. Moreover, molecular heterogeneity between organ LECs remains poorly understood, especially when compared to the increasing knowledge of blood vascular heterogeneity. High throughput single cell approaches may provide an alternative, unbiased and complementary method for identifying and characterising LEC progenitors from different lineages, to compare LECs in different parts of the lymphatic tree and to investigate organ-specific LEC differentiation. In particular, single-cell RNA sequencing is a rapidly evolving technology that can be used to sequence the transcriptomes of individual cells from dissociated tissues,
enabling the identification of different cell (sub)-types and their transcriptional states whilst also allowing the inference of cell transitions to predict lineage relationships. For example, an inferred differentiation ‘trajectory’, which can be obtained by plotting a gradient of gene expression [147] or the ratio of spliced to unspliced mRNA molecules [148] for transcriptionally related cell types along an axis, is used to describe ‘pseudotime’ [149]. This method, in turn, may help to infer LEC lineages, as has previously been done for other cell types. Alternatively, natural mutations, such as those occurring in mitochondrial DNA [150] or the introduction of heritable barcodes [151] could be used to retrospectively predict lymphatic lineage by computational approaches and is a technique which could also be applied to human tissue samples. The advent of spatial transcriptomics [152] may significantly enhance our insights into organ-specific lymphatic formation. For example, to determine the cellular and molecular composition of niches that promote the development of LECs in different organs. Transcription, however, does not necessarily indicate protein expression and, therefore, the development of single cell proteomic technologies will be important to understand functional heterogeneity of LECs in different organs [153].

**Intersectional genetics**

Despite the identification of multiple lymphatic lineages, their functional relevance is challenging to establish. In particular, Cre expression in other, unwanted cell types complicates the interpretation of Cre-mediated lineage tracing and hinders the ability to ablate candidate genes specifically in LECs. For example, deletion of second heart field-derived lymphatics by knockout of Prox1 using Isl1-Cre results in agenesis of cardiac ventral lymphatic vessels, but also defects in the dorsal lymphatics [99] that are not directly targeted by Isl1-Cre [99, 103]; this could be explained by a requirement for PROX1 in the myocardium that also arises from an Isl1 lineage [154] and may regulate lymphatic development. To increase the specificity of targeting organ-specific populations of cells in the mouse, two different fragments of Cre might be expressed from promoters with overlapping expression, so that complementation causes the full Cre protein to be selectively expressed in cells that activate both promoters [155]. Alternatively, two different site-specific recombinases could be used in sequence or in parallel, for example, the Cre-loxP system together with the Dre-Rox system, which uses the Dre recombinase from the D6 bacteriophage and its target recombination sites, termed ‘Rox’ [156]. For example, a Prox1- RSR-CreER T2 mouse has recently been described, in which Dre expression is required to activate CreER T2 in Prox1+ cells [157]. As such, mating this line with an appropriate Dre recombinase line that is active in the second heart field could facilitate genetic recombination in the cardiac LEC lineage. This approach thereby surmounts the caveats of single promoter-based approaches. Moreover, intersectional genetics could be applied for targeted cell ablation approaches, for example by expressing diptheria toxin [158] or its receptor [159] in LECs from different origins, to distinguish roles for venous- and non-venous-derived LECs in lymphatic vessels during development, or thereafter, in health and disease.

**Conclusion**

The acquisition of knowledge of the cellular dynamics and origins of LECs in embryonic development is rapidly progressing. With the help of classical and emerging technologies, we anticipate a better understanding of lymphangiogenesis and lymphvasculogenesis and the origin of lymphatic lineages. Ultimately, an improved understanding of lymphatic development should significantly advance the study of lymphatic function in health as well as in disease, and potentially inform therapeutic approaches and regenerative medicine to treat the wide spectrum of diseases in which lymphatic vessels have been implicated.

**Acknowledgements** CR is supported by funding from the British Heart Foundation (FS/18/65/34186) and Wellcome (205099/Z/16/Z), DAL is supported by funding from Kidney Research UK (Paed_RP_10_2018, IN_012_2019), the Rosetrees Trust (PGS19-2/10174) and Wellcome (220895/Z/20/Z). DJJ is supported by the UCL MB/PhD programme, a Child Health Research PhD studentship and a Rosetrees Trust PhD Plus award (PhD2020/100012). PSJS is supported by funding from the Leducq Foundation (15CDV01) and the British Heart Foundation (RG151431880). DJJ, DAL and PSJS are supported by the National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made.

**References**

1. Petrova TV, Koh GY (2020) Biological functions of lymphatic vessels. Science 369:eaux4063. https://doi.org/10.1126/science.aaux4063
2. Oliver G, Kipnis J, Randolph GJ, Harvey NL (2020) The lymphatic vasculature in the 21st century: novel functional roles in
homeostasis and disease. Cell 182:270–296. https://doi.org/10.1016/j.cell.2020.06.039
3. Ulvmar MH, Mäkinen T (2016) Heterogeneity in the lymphatic vascular system and its origin. Cardiovasc Res 111:310–321. https://doi.org/10.1093/cvr/cvw175
4. Aspelund A, Antila S, Proulx ST et al (2015) A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 212:991–999. https://doi.org/10.1084/jem.20142290
5. Louveau A, Smirnov I, Keyes TJ et al (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523:337–341. https://doi.org/10.1038/nature14432
6. Jacob L, Boisserand LSB, Geraldo LHM et al (2019) Anatomy and function of the vertebral column lymphatic network in mice. Nat Commun 10:4594. https://doi.org/10.1038/s41467-019-12568-w
7. Ma Q, Decker Y, Müller A et al (2019) Clearance of cerebrospinal fluid from the sacral spine through lymphatic vessels. J Exp Med 216:2492–2502. https://doi.org/10.1084/jem.20190351
8. Antila S, Karaman S, Nurmi H et al (2017) Development and plasticity of meningeal lymphatic vessels. J Exp Med 214:3645–3667. https://doi.org/10.1084/jem.20170391
9. Castranova D, Samasa B, Venero Galanternik M et al (2021) Live imaging of intracranial lymphatics in the zebrafish. Circ Res 128:42–58. https://doi.org/10.1161/CIRCRESAHA.120.317372
10. Bolte AC, Dutta AB, Hurt ME et al (2020) Meningeal lymphatic dysfunction exacerbates traumatic brain injury pathogenesis. Nat Commun 11:4524. https://doi.org/10.1038/s41467-020-18113-4
11. Ahn JH, Cho H, Kim J-H et al (2019) Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. Nature 572:62–66. https://doi.org/10.1038/s41586-019-1419-5
12. Da Mesquita S, Louveau A, Vaccari A et al (2018) Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease. Nature 560:185–191. https://doi.org/10.1038/s41586-018-0368-8
13. Betterman KL, Harvey NL (2016) The lymphatic vasculature: development and role in shaping immunity. Immunol Rev 271:276–292. https://doi.org/10.1111/imm.12413
14. Randolph GJ, Ivanov S, Zinselmeyer BH, Scallan JP (2017) The lymphatic system: integral roles in immunity. Annu Rev Immunol 35:31–52. https://doi.org/10.1146/annurev-immunol-040115-055534
15. Steele MM, Lain AW (2021) Afferent lymphatic transport and peripheral tissue immunity. J Immunol 206:264–272. https://doi.org/10.4049/jimmunol.2001060
16. Hsu M, Rayasam A, Kijak JA et al (2019) Neuroinflammation-induced lymphangiogenesis near the cribiform plate contributes to drainage of CNS-derived antigens and immune cells. Nat Commun 10:229. https://doi.org/10.1038/s41467-018-01863-0
17. Louveau A, Herz J, Alme MN et al (2018) CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat Neurosci 21:1380–1391. https://doi.org/10.1038/s41593-018-0227-9
18. Vieira JM, Normán S, Villa Del Campo C et al (2018) The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction. J Clin Invest 128:3402–3412. https://doi.org/10.1172/JCI97192
19. Trincot CE, Xu W, Zhang H et al (2019) Adrenomedullin induces cardiac lymphangiogenesis after myocardial infarction and regulates cardiac edema via connexin 43. Circ Res 124:101–113. https://doi.org/10.1161/CIRCRESAHA.118.313835
20. Liu X, De la Cruz E, Gu X et al (2020) Lymphoangiocrine signals promote cardiac growth and repair. Nature 588:705–711. https://doi.org/10.1038/s41586-020-2998-x
21. Harrison MR, Feng X, Mo G et al (2019) Late developing cardiac lymphatic vasculature supports adult zebrafish heart function and regeneration. Elife. https://doi.org/10.7554/Elife.42762
22. Klotz L, Normán S, Vieira JM et al (2015) Cardiac lymphatics are heterogeneous in origin and respond to injury. Nature 522:62–67. https://doi.org/10.1038/nature14483
23. Song E, Mao T, Dong H et al (2020) VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. Nature 577:689–694. https://doi.org/10.1038/s41586-019-1912-x
24. Le CP, Nowell CJ, Kim-Fuchs C et al (2016) Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nat Commun 7:10634. https://doi.org/10.1038/ncomms10634
25. Jang JY, Koh YJ, Lee S-H et al (2013) Conditional ablation of LYVE-1+ cells unveils defensive roles of lymphatic vessels in intestine and lymph nodes. Blood 122:2151–2161. https://doi.org/10.1182/blood-2013-01-478941
26. Randolph GJ, Miller NE (2014) Lymphatic transport of high-density lipoproteins and chylomicrons. J Clin Invest 124:929–935. https://doi.org/10.1172/JCI71610
27. Escobedo B, Proulx ST, Karaman S et al (2016) Restoration of lymphatic function rescues obesity in Prox1-haploinsufficient mice. JCI Insight. https://doi.org/10.1172/jci.insight.85096
28. Zhang F, Zarkada G, Han J et al (2018) Lacteal junction zipper protects against diet-induced obesity. Science 361:599–603. https://doi.org/10.1126/science.aap9331
29. Peña-Jimenez D, Fontenete S, Megias D et al (2019) Lymphatic vessels interact dynamically with the hair follicle stem cell niche during skin regeneration in vivo. EMBO J 38:e101688. https://doi.org/10.15252/embj.2019101688
30. Gur-Cohen S, Yang H, Baksh SC et al (2019) Stem cell-driven lymphatic remodeling coordinates tissue regeneration. Science 366:1218–1225. https://doi.org/10.1126/science.aay4509
31. Jakus Z, Glegehorn JP, Enis DR et al (2014) Lymphatic function is required prenatally for lung inflation at birth. J Exp Med 211:815–826. https://doi.org/10.1084/jem.20132308
32. Sabin FR (1902) On the origin of the lymphatic system from the veins and the development of the lymph hearts and thoracic duct in the pig. Am J Anat 1:367–389. https://doi.org/10.1002/aja.100010310
33. Sabin FR (1904) On the development of the superficial lymphatics in the skin of the pig. Am J Anat 3:183–195. https://doi.org/10.1002/aja.100030205
34. Baertjes WA (1908) On the origin of the mesenteric sac and thoracic duct in the embryo pig. Am J Anat 8:303–318. https://doi.org/10.1002/aja.100080111
35. Lewis FT (1909) The first lymph glands in rabbit and human embryos. Anat Rec 3:341–353. https://doi.org/10.1002/ar.1090030604
36. Huntington GS, McClure CWF (1910) The anatomy and development of the jugular lymph sacs in the domestic cat (Felis domestica). Am J Anat 10:177–312. https://doi.org/10.1002/aja.1000100108
37. Wigle JT, Oliver G (1999) Prox1 function is required for the development of the murine lymphatic system. Cell 98:769–778. https://doi.org/10.1016/s0092-8674(00)81511-1
38. Wigle JT, Harvey N, Detmar M et al (2002) An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 21:1505–1513. https://doi.org/10.1093/emboj/21.7.1505
39. Johnson NC, Dillard ME, Baluk P et al (2008) Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. Genes Dev 22:3282–3291. https://doi.org/10.1101/gad.1727208
40. Kaipainen A, Korhonen J, Mustonen T et al (1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92:3566–3570. https://doi.org/10.1073/pnas.92.8.3566

41. Breiteneder-Geleff S, Soleiman A, Horvat R et al (1999) Podoplanin—a specific marker for lymphatic endothelium expressed in angiosarcoma. Verh Dtsch Ges Pathol 83:270–275

42. Banerji S, Ni J, Wang SX et al (1999) LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 144:789–801. https://doi.org/10.1083/jcb.144.4.789

43. Bafaret DJ, Moulding D, Kolatsi-Joannou M et al (2019) Spatiotemporal dynamics and heterogeneity of renal lymphatics in mammalian development and cystic kidney disease. Elife 8:e48183. https://doi.org/10.7554/EI Life.48183

44. Hägerling R, Pollmann C, Andreas M et al (2013) A novel multistep mechanism for initial lymphangiogenesis in mouse embryos based on ultramicroscopy. EMBO J 32:629–644. https://doi.org/10.1038/emboj.2012.340

45. François M, Short K, Secker GA et al (2012) Segmental territories along the cardinal veins generate lymph sacs via a ballooning mechanism during embryonic lymphangiogenesis in mice. Dev Biol 364:89–98. https://doi.org/10.1016/j.ydbio.2011.12.032

46. Okuda KS, Astin JW, Misa JP et al (2012) lyve1 expression reveals novel lymphatic vessels and new mechanisms for lymphatic vessel development in zebrafish. Development 139:2381–2391. https://doi.org/10.1242/dev.077701

47. Yaniv K, Isogai S, Castranova D et al (2006) Live imaging of lymphatic development in the zebrafish. Nat Med 12:711–716. https://doi.org/10.1038/nm1427

48. Küchler AM, Gjini E, Peterson-Maduro J et al (2006) Development of the zebrafish lymphatic system requires VEGF signaling. Curr Biol 16:1244–1248. https://doi.org/10.1016/j.cub.2006.05.026

49. Saito E, Isogai S, Deguchi T et al (2020) Prox1 physically and functionally interacts with COUP-TFII to specify lymphatic endothelial cell identity. Mol Cell Biol 27:1456:643–647. https://doi.org/10.1038/nature07391

50. Srivivasan RS, Geng X, Yang Y et al (2010) The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cells. Genes Dev 24:696–707. https://doi.org/10.1101/gad.1859310

51. Tai-Nagara I, Hasumi Y, Kusumoto D et al (2020) Blood and lymphatic systems are segregated by the FLCN tumor suppressor. Nat Commun 11:6314. https://doi.org/10.1038/s41467-020-20156-6

52. Gale NW, Prevo R, Espinosa J et al (2007) Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Mol Cell Biol 27:595–604. https://doi.org/10.1128/MCB.01503-06

53. Lin C-J, Lin C-Y, Chen C-H et al (2012) Partitioning the heart: aortic origin for the cardinal vein in mammals. Development 139:3277–3299. https://doi.org/10.1242/dev.01503-06

54. Gerhardt H, Golding M, Fruttiger M et al (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161:1163–1177. https://doi.org/10.1083/jcb.200302047

55. Ruhrberg C, Gerhardt H, Golding M et al (2002) Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 16:2684–2698. https://doi.org/10.1016/j.发育.2002

56. Kerkkamien MJ, Haiko P, Sainio K et al (2004) Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5:74–80. https://doi.org/10.1038/nim1013

57. Srinivasan RS, Dillard ME, Lagutin OV et al (2007) Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev 21:2422–2432. https://doi.org/10.1101/gad.1588407

58. Haiko P, Makinen T, Keskitalo S et al (2008) Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol Cell Biol 28:4843–4850. https://doi.org/10.1128/MCB.02214-07

59. Zhang Y, Ulvmar MH, Stanczuk L et al (2018) Heterogeneity in VEGFR3 levels drives lymphatic vessel hyperplasia through cell-autonomous and non-cell-autonomous mechanisms. Nat Commun 9:1296. https://doi.org/10.1038/s41467-018-03692-0

60. Srinivasan RS, Escobedo N, Yang Y et al (2014) The Prox1-VEGFR3 feedback loop maintains the identity and the number of lymphatic endothelial cell progenitors. Genes Dev 28:2175–2187. https://doi.org/10.1101/gad.216226.113

61. Frye M, Taddei A, Dierkes C et al (2018) Matrix stiffness controls lymphatic vessel formation through regulation of a GATA2-dependent transcriptional program. Nat Commun 9:1511. https://doi.org/10.1038/s41467-018-03959-6

62. Xu Y, Yuan L, Mak J et al (2010) Neuruplin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol 188:115–130. https://doi.org/10.1083/jcb.200903137

63. Yuan L, Moyon D, Pardanaud L et al (2002) Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129:4797–4806

64. Lin C-J, Lin C-Y, Chen C-H et al (2012) Partitioning the heart: mechanisms of cardiac septation and valve development. Development 139:3277–3299. https://doi.org/10.1242/dev.063495

65. Yang Y, García-Verdugo JM, Soriano-Navarro M et al (2012) Lymphoid endothelial progenitors bud from the cardinal vein and intersomitic vessels in mammalian embryos. Blood 120:2340–2348. https://doi.org/10.1182/blood-2012-05-428607

66. Lee S, Kang J, Yoo J et al (2009) Prox1 physically and functionally interacts with Coup-TFII to specify lymphatic endothelial cell fate. Blood 113:1856–1859. https://doi.org/10.1182/blood-2008-03-145789

67. Aranguren XL, Beersens M, Coppello G et al (2013) Coup-TFII orchestrates venous and lymphatic endothelial identity by homo-tertiary dimerization with PROX1. J Cell Sci 126:1164–1175. https://doi.org/10.1242/jcs.116293

68. Francois M, Caprini A, Hosking B et al (2008) Sox18 induces development of the lymphatic vasculature in mice. Nature 456:643–647. https://doi.org/10.1038/nature07391
76. Janssen L, Dupont L, Bekhouche M et al (2016) ADAMTS3 activity is mandatory for embryonic lymphangiogenesis and regulates placental angiogenesis. Angiogenesis 19:53–65. https://doi.org/10.1007/s10456-015-9488-z

77. Bos FL, Caunt M, Peterson-Maduro J et al (2011) CCBE1 is essential for mammalian lymphatic vascular development and enhances the lymphangiogenic effect of vascular endothelial growth factor-C in vivo. Circ Res 109:486–491. https://doi.org/10.1161/CIRCRESAHA.111.250738

78. Pichol-Thievend C, Betterman KL, Liu X et al (2018) A blood capillary plexus-derived population of progenitor cells contributes to genesis of the dermal lymphatic vasculature during embryonic development. Developm. https://doi.org/10.1242/dev.160184

79. Martinez-Corral I, Ulmar MH, Stanczuk L et al (2015) Nonvenous origin of dermal lymphatic vasculature. Circ Res 116:1649–1654. https://doi.org/10.1161/CIRCRESAHA.116.306170

80. Stone OA, Stainier DYR (2019) Paraxial mesoderm is the major source of lymphatic endothelium. Dev Cell 50:247-255.e3. https://doi.org/10.1016/j.devcel.2019.04.034

81. Stanczuk L, Martinez-Corral I, Ulmar MH et al (2015) cKit lineage hemogenic endothelium-derived cells contribute to mesenteric lymphatic vessels. Cell Rep 10:1708–1721. https://doi.org/10.1016/j.celrep.2015.02.026

82. Gancz D, Raftery BC, Perlmuter G et al (2019) Distinct origins and molecular mechanisms contribute to lymphatic formation during cardiac growth and regeneration. Elife 8:e4153. https://doi.org/10.7554/eLife.44153

83. Kulkarni RM, Herman A, Ikegami M et al (2011) Lymphatic genes and molecular mechanisms contribute to genesis of the dermal lymphatic vasculature during embryonic development. Developm. https://doi.org/10.1242/dev.160184

84. Koltowska K, Lagendijk AK, Pichol-Thievend C et al (2015) Angiogenesis (2021) 24:271–288

85. van Impel A, Zhao Z, Hermkens DMA et al (2014) Divergence of zebrafish and mouse lymphatic cell fate specification pathways. Development 141:1228–1238. https://doi.org/10.1242/dev.105031

86. El-Brolosy MA, Kontarakis Z, Rossi A et al (2019) Genetic compensation triggered by mutant mRNA degradation. Nature 568:193–197. https://doi.org/10.1038/s41586-019-1064-z

87. Jerafi-Vider A, Moshe N, Hen G et al (2020) VEGFC induced prox1b mutants develop a lymphatic vasculature, and prox1b does not specifically mark lymphatic endothelial cells. PLoS ONE 6:e28934. https://doi.org/10.1371/journal.pone.0028934

88. Bahary N, Goishi K, Stuckenholz C et al (2007) Duplicate Vegf/A genes and orthologues of the KDR receptor tyrosine kinase family mediate vascular development in the zebrafish. Blood 110:3627–3636. https://doi.org/10.1182/blood-2006-04-016378

89. Koltowska K, Lagendijk AK, Pichol-Thievend C et al (2015) Angiogenesis (2021) 24:271–288

90. Wang G, Muhl L, Padberg Y et al (2020) Specific fibroblast growth factor-C in vivo. Circ Res 109:486–491. https://doi.org/10.1161/CIRCRESAHA.111.250738

91. Sha YR, Fujita M, Butler M et al (2012) Chemokine signaling directs trunk lymphatic network formation along the preexisting blood vasculature. Dev Cell 22:824–836. https://doi.org/10.1016/j.devcel.2012.01.011

92. Eng TC, Chen W, Okuda KS et al (2019) Zebrafish facial lymphatics develop through sequential addition of venous and non-venous progenitors. EMBO Rep 20(5):e47079. https://doi.org/10.15252/embr.201847079

93. van Impel A, Zhao Z, Hermkens DMA et al (2014) Divergence of zebrafish and mouse lymphatic cell fate specification pathways. Development 141:1228–1238. https://doi.org/10.1242/dev.105031

94. Tao S, Witte M, Bryson-Richardson RJ et al (2011) Zebrafish prox1b mutants develop a lymphatic vasculature, and prox1b does not specifically mark lymphatic endothelial cells. PLoS ONE 6:e28934. https://doi.org/10.1371/journal.pone.0028934

95. Bahary N, Goishi K, Stuckenholz C et al (2007) Duplicate Vegf/A genes and orthologues of the KDR receptor tyrosine kinase family mediate vascular development in the zebrafish. Blood 110:3627–3636. https://doi.org/10.1182/blood-2006-04-016378

96. El-Brolosy MA, Kontarakis Z, Rossi A et al (2019) Genetic compensation triggered by mutant mRNA degradation. Nature 568:193–197. https://doi.org/10.1038/s41586-019-1064-z

97. Vogrin AJ, Bower NI, Gunzburg MJ et al (2019) Evolutionary differences in the vegf/vegfr code reveal organotypic roles for the endothelial cell receptor kdr in developmental lymphangiogenesis. Cell Rep 28:2023–2036.e4. https://doi.org/10.1016/j.celrep.2019.07.055

98. Das RN, Yaniv K (2020) Discovering new progenitor cell populations through lineage tracing and in vivo imaging. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a035618

99. Maruyama K, Miyagawa-Tomita S, Mizukami K et al (2019) IsI1-expressing non-venous cell lineage contributes to cardiac lymphatic vessel development. Dev Biol 452:134–143. https://doi.org/10.1016/j.ydbio.2019.05.002

100. Tammela T, Saaristo A, Lohela M et al (2005) Angiopoietin-1 source of lymphatic endothelium. Dev Cell 50:247-255.e3. https://doi.org/10.1016/j.devcel.2005.07.002

101. Neal A, Nornes S, Payne S et al (2019) Venous identity requires BMP signalling through ALK3. Nat Commun 10:453. https://doi.org/10.1038/s41467-019-08315-w

102. Tammela T, Saaristo A, Lohela M et al (2005) Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 105:4642–4648. https://doi.org/10.1182/blood-2004-08-3327

103. Lioux G, Liu X, Temiño S et al (2020) A second heart field-derived vasulocgetic niche contributes to cardiac lymphatics. Dev Cell 52:350-363.e6. https://doi.org/10.1016/j.devcel.2019.12.006

104. Tammela T, Saaristo A, Lohela M et al (2005) Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 105:4642–4648. https://doi.org/10.1182/blood-2004-08-3327

105. Lioux G, Liu X, Temiño S et al (2020) A second heart field-derived vasulocgetic niche contributes to cardiac lymphatics. Dev Cell 52:350-363.e6. https://doi.org/10.1016/j.devcel.2019.12.006

106. Tammela T, Saaristo A, Lohela M et al (2005) Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 105:4642–4648. https://doi.org/10.1182/blood-2004-08-3327

107. Tammela T, Saaristo A, Lohela M et al (2005) Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 105:4642–4648. https://doi.org/10.1182/blood-2004-08-3327

108. Gentek R, Ghigo C, Hoeffel G et al (2018) Hemogenic endothelium-derived cells contribute to mesentric lymphatic vessels. Cell Rep 10:1708–1721. https://doi.org/10.1016/j.celrep.2015.02.026

109. Koltowska K, Lagendijk AK, Pichol-Thievend C et al (2015) Angiogenesis (2021) 24:271–288
embryo. Blood 124:2523–2532. https://doi.org/10.1182/blood-2013-12-545939

110. Hägerling R, Hoppe E, Dierkes C et al (2018) Distinct roles of VE-cadherin for development and maintenance of specific lymph vessel beds. EMBO J 37(22):e98271. https://doi.org/10.15252/embj.201798271

111. Wang Y, Jin Y, Mäe MA et al (2017) Smooth muscle cell recruitment to lymphatic vessels requires PDGFB and impacts vessel size but not identity. Development 144:3590–3601. https://doi.org/10.1242/dev.147967

112. Bovay E, Sabine A, Prat-Luri B et al (2018) Multiple roles of lymphatic vessels in peripheral lymph node development. J Exp Med 215:2760–2777. https://doi.org/10.1084/jem.20180217

113. Zhang Y, Daubel N, Stritt S, Mäkinen T (2018) Transient loss of venous integrity during developmental vascular remodeling leads to red blood cell extravasation and clearance by lymphatic vessels. Development 145(3):dev156745. https://doi.org/10.1242/dev.156745

114. Luo L, Ambrozkiewicz MC, Benseler F et al (2020) Optimizing nervous system-specific gene targeting with Cre driver lines: prevalence of germline recombination and influencing factors. Neuron 106:37-65.e5. https://doi.org/10.1016/j.neuron.2020.01.008

115. Heffner CS, Herbert Pratt C, Babiuq RP et al (2012) Supporting conditional mouse mutagenesis with a comprehensive Cre characterization resource. Nat Commun 3:1218. https://doi.org/10.1038/ncomms2186

116. Álvarez-Aznar A, Martínez-Corral I, Daubel N et al (2020) Tamoxifen-independent recombination of reporter genes limits lineage tracing and mosaic analysis using CreERT2 lines. Transgenic Res 29:53–68. https://doi.org/10.1007/s11248-019-00177-8

117. Hayashi S, McMahon AP (2002) Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 244:305–318. https://doi.org/10.1006/dbio.2002.0597

118. Reinert RB, Kantz J, Misfeldt AA et al (2012) Tamoxifen-induced Cre-loxP recombination is prolonged in pancreatic islets of adult mice. PLoS ONE 7:e33529. https://doi.org/10.1371/journal.pone.0033529

119. Ved N, Curran A, Ashcroft FM, Sparrow DB (2019) Tamoxifen administration in pregnant mice can be deleterious to both mother and embryo. Lab Anim 53:630–633. https://doi.org/10.1177/0023677219856918

120. Lizen B, Claus M, Jeannotte L et al (2015) Perinatal induction of lymphatic vessels in peripheral lymph node development. J Exp Biol 218:3500–3510. https://doi.org/10.1242/dev.147967

121. Ved N, Curran A, Ashcroft FM, Sparrow DB (2019) Tamoxifen administration in pregnant mice can be deleterious to both mother and embryo. Lab Anim 53:630–633. https://doi.org/10.1177/0023677219856918

122. Lizen B, Claus M, Jeannotte L et al (2015) Perinatal induction of lymphatic vessels in peripheral lymph node development. J Exp Biol 218:3500–3510. https://doi.org/10.1242/dev.147967

123. Pomplun D, Florian S, Schulz T et al (2007) Alterations of pancreatic beta-cell mass and islet number due to Ins2-controlled expression of Cre recombinase: RIP-Cre revisited; part 2. Horm Metab Res 39:336–340. https://doi.org/10.1055/s-2007-976538

124. Brash JT, Bolton RL, Rashbrook VS et al (2020) Tamoxifen-activated CreERT impairs retinal angiogenesis independently of gene deletion. Circ Res 127:849–850. https://doi.org/10.1161/CIRCRESAHA.120.317025

125. Prummel KD, Nieuwenhuize S, Mosimann C (2020) The lateral plate mesoderm. Development 147:dev175059. https://doi.org/10.1242/dev.175059

126. Chong DC, Koo Y, Xu K et al (2011) Stepwise arteriovenous fate acquisition during mammalian vasculogenesis. Dev Dyn 240:2153–2165. https://doi.org/10.1002/dvdy.22706

127. Wilting J, Aref Y, Huang R et al (2006) Dual origin of avian lymphatics. Dev Biol 292:165–173. https://doi.org/10.1016/j.ydbio.2005.12.043

128. Wilting J, Papoutsi M, Schneider M, Christ B (2000) The lymphatic endothelium of the avian wing is of somitic origin. Dev Dyn 217:271–278. https://doi.org/10.1029/S2107/0177(200003)217:3%3C271::AID-DVDCY%3E3.0.CO;2-2

129. Cortes C, Francou A, De Bono C, Kelly RG (2018) Epithelial properties of the second heart field. Circ Res 122:142–154. https://doi.org/10.1161/CIRCRESAHA.117.310838

130. Zhuang S, Zhang Q, Zhuang T et al (2013) Expression of Is1 during mouse development. Gene Expr Patterns 13:407–412. https://doi.org/10.1016/j.gep.2013.07.001

131. Verzi MP, McCulley DJ, De Val S et al (2005) The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field. Dev Biol 287:134–145. https://doi.org/10.1016/j.ydbio.2005.08.041

132. Wang X, Chen D, Chen K et al (2017) Endothelium in the pharyngeal arches 3, 4 and 6 is derived from the second heart field. Dev Biol 421:108–117. https://doi.org/10.1016/j.ydbio.2016.12.010

133. Plein A, Fantin A, Denti L et al (2018) Erythro-myeloid progenitors contribute endothelial cells to blood vessels. Nature 562:223–228. https://doi.org/10.1038/s41586-018-0552-x

134. Fantin A, Plein A, Tacconi C et al (2021) KIT is required for fetal liver erythropoiesis but dispensable for angiogenesis. BioRxiv. https://doi.org/10.1101/2021.01.15.426801

135. Chen MJ, Yokomizo T, Zeigler BM et al (2009) Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature 457:887–891. https://doi.org/10.1038/nature07619

136. Gritz E, Hirschi KK (2016) Specification and function of hemogenic endothelium during embryogenesis. Cell Mol Life Sci 73:1547–1567. https://doi.org/10.1007/s00018-016-2134-0

137. Liu J, Willet SG, Bankaitis ED et al (2013) Non-parallel recombination limits Cre-LoxP-based reporters as precise indicators of conditional genetic manipulation. Genetics 193:436–442. https://doi.org/10.1002/dvg.22384

138. Guilliams M, Thierry GR, Bonnardel J, Bajenoff M (2020) Establishment and maintenance of the macrophage niche. Immunity 52:434–451. https://doi.org/10.1016/j.immuni.2020.02.015

139. Cho KH, Cheong JS, Ha YS et al (2012) The anatomy of fetal peripheral lymphatic vessels in the head-and-neck region: an immunohistochemical study. J Anat 220:102–111. https://doi.org/10.1111/j.1469-7580.2011.01441.x

140. Jin ZW, Nakamura T, Yu HC et al (2010) Fetal anatomy of peripheral lymphatic vessels: a D2–40 immunohistochemical study using an 18-week human fetus (CRL 155 mm). J Anat 216:671–682. https://doi.org/10.1111/j.1469-7580.2010.01229.x

141. von Kaisenberg CS, Wilting J, Dörk T et al (2010) Lymphatic capillary hypoplasia in the skin of fetuses with increased nuchal translucency and Turner’s syndrome: comparison with trisomies and controls. Mol Hum Reprod 16:778–789. https://doi.org/10.1093/molehr/gaq035

142. Liu T-L, Upadhyayula S, Milkie DE et al (2018) Observing the cell in its native state: imaging subcellular dynamics in multicellular organisms. Science 360:eaalq392. https://doi.org/10.1126/science.aalq392
143. Homan KA, Gupta N, Kroll KT et al (2019) Flow-enhanced vascularization and maturation of kidney organoids in vitro. Nat Methods 16:255–262. https://doi.org/10.1038/s41592-019-0325-y

144. Planas-Paz L, Strlic B, Goedecke A et al (2012) Mechanoinduction of lymph vessel expansion. EMBO J 31:788–804. https://doi.org/10.1038/emboj.2011.456

145. Schindler SE, McCall JG, Yan P et al (2015) Photo-activatable Cre recombinase regulates gene expression in vivo. Sci Rep 5:13627. https://doi.org/10.1038/srep13627

146. Takao T, Sato M, Maruyama T (2020) Optogenetic regulation of embryo implantation in mice using photoactivatable CRISPR-Cas9. Proc Natl Acad Sci USA 117:28579–28581. https://doi.org/10.1073/pnas.2016850117

147. Wagner DE, Klein AM (2020) Lineage tracing meets single-cell omics: opportunities and challenges. Nat Rev Genet 21:410–427. https://doi.org/10.1038/s41576-020-0223-2

148. La Manno G, Soldatov R, Zeisel A et al (2018) RNA velocity of single cells. Nature 560:494–498. https://doi.org/10.1038/s41586-018-0414-6

149. Tam PPL, Ho JWK (2020) Cellular diversity and lineage trajectory: insights from mouse cell transcriptomes. Development 147:dev179788. https://doi.org/10.1242/dev.179788

150. Ludwig LS, Lareau CA, Ulirsch JC et al (2019) Lineage tracing in humans enabled by mitochondrial mutations and single-cell genomics. Cell 176:1325-1339.e22. https://doi.org/10.1016/j.cell.2019.01.022

151. Raj B, Wagner DE, McKenna A et al (2018) Simultaneous single-cell profiling of lineages and cell types in the vertebrate brain. Nat Biotechnol 36:442–450. https://doi.org/10.1038/nbt.4103

152. Liao J, Lu X, Shao X et al (2021) Uncovering an organ’s molecular architecture at single-cell resolution by spatially resolved transcriptomics. Trends Biotechnol 39:43–58. https://doi.org/10.1016/j.tibtech.2020.05.006

153. Labib M, Kelley SO (2020) Single-cell analysis targeting the proteome. Nat Rev Chem. https://doi.org/10.1038/s41570-020-0162-7

154. Risebro CA, Searles RG, Melville AAD et al (2009) Prox1 maintains muscle structure and growth in the developing heart. Development 136:495–505. https://doi.org/10.1242/dev.030007

155. Hirrlinger J, Scheller A, Hirrlinger PG et al (2009) Split-cre complementation indicates coincident activity of different genes in vivo. PLoS ONE 4:e4286. https://doi.org/10.1371/journal.pone.0004286

156. Anastassiadis K, Fu J, Patsch C et al (2009) Dre recombinase, like Cre, is a highly efficient site-specific recombinase in E. coli, mammalian cells and mice. Dis Model Mech 2:508–515. https://doi.org/10.1242/dmm.003087

157. Han X, Zhang Z, He L et al (2021) A suite of new Dre recombinase drivers markedly expands the ability to perform intersectional genetic targeting. Cell Stem Cell. https://doi.org/10.1016/j.stem.2021.01.007

158. Ivanova A, Signore M, Caro N et al (2005) In vivo genetic ablation by Cre-mediated expression of diphtheria toxin fragment A. Genesis 43:129–135. https://doi.org/10.1002/gene.20162

159. Buch T, Heppner FL, Tertilt C et al (2005) A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods 2:419–426. https://doi.org/10.1038/nmeth762

160. Bertozzi CC, Schmaier AA, Mericko P et al (2010) Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 116:661–670. https://doi.org/10.1182/blood-2010-02-270876

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.